LNLukas Schak Nielsen

Lukas Schak Nielsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lukas Schak Nielsen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Dunja Kokotovic

    Emergency Surgery Research Group Copenhagen (EMERGE), Department of Hepatic and Gastrointestinal Diseases, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark

    2 shared publications
  • Jakob Burcharth

    Emergency Surgery Research Group Copenhagen (EMERGE), Department of Hepatic and Gastrointestinal Diseases, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark

    2 shared publications
  • Lasse Rehné Jensen

    Emergency Surgery Research Group Copenhagen (EMERGE), Department of Hepatic and Gastrointestinal Diseases, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark

    2 shared publications
  • Thomas Korgaard Jensen

    Emergency Surgery Research Group Copenhagen (EMERGE), Department of Hepatic and Gastrointestinal Diseases, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark

    2 shared publications
  • Trygve Ulvund Solstad

    Emergency Surgery Research Group Copenhagen (EMERGE), Department of Hepatic and Gastrointestinal Diseases, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark

    2 shared publications
  • Anna Gundlund

    Department of Cardiology, Centre B, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Surgeons’ Immediate Postoperative Prediction After Major Emergency Abdominal Surgery

    by Lasse Rehné Jensen, Trygve Ulvund Solstad, Lukas Schak, Dunja Kokotovic, Thomas Korgaard Jensen, Jakob Burcharth

  • Surgeon-perceived intraoperative complexity is associated with early adverse outcomes after major emergency abdominal surgery: a prospective cohort study

    by Lasse Rehné Jensen, Thea Helene Degett, Trygve Ulvund Solstad, Lukas Schak Nielsen, Dunja Kokotovic, Thomas Korgaard Jensen, Jakob Burcharth

    Background Intraoperative complexity in major emergency abdominal surgery lacks a standardized definition and is rarely quantified prospectively. Whether surgeon-perceived intraoperative complexity is associated with short-term postoperative outcomes remains unknown. Methods In this single-center prospective cohort study, 411 patients undergoing major emergency abdominal surgery were included. Immediately after surgery, the operating surgeon rated perceived intraoperative complexity on a 0–10 scale. The association between surgeon-perceived intraoperative complexity and the primary outcome, 30-day unplanned reoperation, was investigated using Fine–Gray regression. The model was adjusted for age, sex, body mass index, performance status, and intraoperative pathology. Secondary outcomes were 30-day mortality, length of stay, and Comprehensive Complication Index. Results Unplanned reoperation occurred in 15% and 30-day mortality in 11%. Higher surgeon-perceived intraoperative complexity was associated with reoperation (sHR 1.20 per point; 95% CI 1.08–1.34). Complexity was also associated with prolonged LOS (β 1.47 days per unit increase; 95% CI 0.93–2.01), higher CCI category (OR 1.24 per unit increase; 95% CI 1.14–1.35), and increased 30-day mortality (OR 1.25; 95% CI 1.07–1.45). Conclusion Surgeon-perceived intraoperative complexity was associated with reoperation, morbidity, and 30-day mortality after major emergency abdominal surgery. These findings suggest that the operating surgeon’s assessment may capture clinically meaningful prognostic information beyond conventional baseline risk factors. External validation and evaluation of inter-rater reproducibility are needed before clinical implementation.

  • Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score 1: A Nationwide Study

    by Lauge Østergaard, Jonas Bjerring Olesen, Jeppe Kofoed Petersen, Lukas Schak Nielsen, Søren Lund Kristensen, Morten Schou, Lars Køber, Emil Fosbøl

    BACKGROUND: Oral anticoagulation is suggested in patients with atrial fibrillation and a CHA 2 DS 2 -VASc score ≥1 (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65–74 years, and sex score). To assess granular differences within CHA 2 DS 2 -VASc 1, the incidence of arterial thromboembolism according to CHA 2 DS 2 -VASc 1 subgroups was examined. METHODS: The Danish National Patient Registry and the Danish Prescription Registry were linked on a nationwide level to identify patients with atrial fibrillation from 2000 to 2021 without oral anticoagulation and categorized according to CHA 2 DS 2 -VASc score: CHA 2 DS 2 -VASc 0 (male and female subjects); CHA 2 DS 2 -VASc 1 (hypertension, heart failure, diabetes, vascular disease, and age 65–74 years); or CHA 2 DS 2 -VASc 2 (age ≥75 years without other risk factors). Female sex was not considered a risk factor in any risk group. The outcome was arterial thromboembolism (ischemic stroke, embolism of extremity, or transient cerebral ischemia). Study groups were compared using Cox regression analysis. RESULTS: We included 26 701 patients with a CHA 2 DS 2 -VASc 0 score; 22 915 with CHA 2 DS 2 -VASc 1 (1483 patients with heart failure, 9066 with hypertension, 843 with diabetes, 770 with vascular disease, and 10 753 who were 65 to 74 years of age); and 14 525 patients with CHA 2 DS 2 -VASc 2 (≥75 years of age without other risk factors). With a median of 1 year of observation time, the cumulative incidence of arterial thromboembolism was 0.6% (n=154 [95% CI, 0.6%–0.8%]), 1.4% (n=16 [95% CI, 0.8%–2.2%]), 1.9% (n=141 [95% CI, 1.6%–2.2%]), 1.7% (n=12 [95% CI, 0.9%–2.9%]), 2.0% (n=13 [95% CI, 1.1%–3.4%]), 2.3% (n=187 [95% CI, 2.0%–2.7%]), and 4.4% (n=533 [95% CI, 4.1%–4.8%]) for CHA 2 DS 2 -VASc 0, heart failure, hypertension, diabetes, vascular disease, age 65 to 74 years (CHA 2 DS 2 -VASc 1), and age ≥75 years (CHA 2 DS 2 -VASc 2), respectively. No statistically significant difference was identified among subgroups of CHA 2 DS 2 -VASc 1 ( P =0.15 for difference). CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA 2 DS 2 -VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA 2 DS 2 -VASc 2) and a higher incidence compared with CHA 2 DS 2 -VASc 0. No statistically significant difference was identified between the subgroups of CHA 2 DS 2 -VASc 1. These findings support current recommendations that patients within this intermediate risk group could be identified with a similar risk of arterial thromboembolism.


  • Temporal changes in incidence, treatment strategies and 1-year re-admission rates in patients with atrial fibrillation/flutter under 65 years of age: A Danish nationwide study

    by Lukas Schak, Jeppe Kofoed Petersen, Naja Emborg Vinding, Charlotte Andersson, Peter E. Weeke, Søren Lund Kristensen, Anna Gundlund, Morten Schou, Lars Køber, Emil Loldrup Fosbøl, et al.